Pompano Beach, FL, March 13, 2018 — BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, announced today the addition of Dr. Felix Amon, who will consult BSEM with Pharmaceutical Business Development.
[Read more…]
ORIG3N, World’s Largest Blood Cell Repository for iPS Cell Production
ORIG3N, an innovative biotech company that creating the world’s largest blood cell repository for induced pluripotent stem cell (iPS cell) production. I first met James Lovgren, Chief Business Officer of ORIG3N, at the World Stem Cell Summit in 2015. As a result of that connection and conversation, I am pleased to share this interview with him below. [Read more…]
Major Milestone for Stem Cells – 300K Scientific Publications
Wow, this is a big moment for the stem cell community. We officially crossed 300,000 stem cell publications released to PubMed.gov. PubMed is a service of the U.S. National Library of Medicine and NIH that comprises more than 27 million citations for biomedical literature.[1] It is the largest and comprehensive global database that exists for scientific publications. [Read more…]
Biostage Announces the Use of Its Esophageal Implant Product Candidate in a Patient
Procedure was approved via the FDA’s single-use expanded access program and was performed at a major U.S. hospital.
HOLLISTON, Mass., Aug. 7, 2017 /PRNewswire/ — Biostage Inc., (Nasdaq: BSTG), (“Biostage” or the “Company”), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening conditions of the esophagus, bronchus and trachea, today announced the use of Biostage’s Cellspan Esophageal Implant product candidate in a patient at a major U.S. hospital via an FDA-approved single-use expanded access application.
Growing Stem Cells in Suspension Bioreactors with Dr. Angel of Accellta
Dr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta, has more than 30 years of experience guiding the business development efforts of new and established companies across the Israeli pharmaceutical industry. Dr. Angel was formerly Vice President of R&D at Proteologics Ltd. and at D-Pharm Biopharmaceuticals. Before those positions, he served as the head of pharmacology in Synthelabo (now Sanofi) where he launched blockbuster drugs such as Xatral, Ambien and Mizollen into the marketplace. [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 24
- Next Page »